with an Overweight rating and $50 price target Septerna’s powerful platform enables efficient discovery of differentiated G-protein-coupled receptor targeting therapeutics, and GPCRs represent a ...

Oct 25 (Reuters) - Septerna's (SEPN.O), opens new tab shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of $970 million. The company's ...

Celebrating his company’s upsized initial public offering (IPO), Septerna CEO Jeffrey Finer ... On the same day last month, Bicara Therapeutics, MBX Bioscences and Zenas BioPharma went public ...

Shares of Septerna SEPN surged 51% on May 14 after ... Several other companies like Amgen AMGN and Viking Therapeutics are also making rapid progress in the development of GLP-1-based candidates ...

acquiring Carmot Therapeutics and partnering with Zealand, and AstraZeneca, partnering with Eccogene, have done. We should also note that while Novo's deal with Septerna involves a $195m upfront ...

Dr. Kim joins Septerna from Design Therapeutics, where he served as Chief Medical Officer and led the clinical advancement of the company’s pipeline of small molecule genomic therapeutics.

The deal is valued at up to $2.2bn, including more than $200m in upfront and near-term payments to Septerna. The partnership centres on the discovery and development of oral therapeutics aimed at ...

Danish pharmaceutical company Novo Nordisk has signed a collaboration deal with U.S. biotech Septerna that will see the two companies develop pills to treat obesity, type 2 diabetes and other ...

The deal is big for a Bay Area drug industry in need of big wins. Septerna shares surged 55% in early trading. Peninsula startup nets Nobel winner, $100M to change drug discovery How taming a ...

(Reuters) -Septerna's shares rose about 31% in their ... Biotechnology firms MBX Biosciences and TPG-backed Bicara Therapeutics went public last month, with shares trading 33% and 25.6% above ...